 |
|
|
| |
Safety of Ribavirin-containing Regimens of ABT-450/r, ABT-333, and ABT-267 for the Treatment of HCV Genotype 1 Infection and Efficacy in Subjects With Ribavirin Dose Reductions
|
| |
| |
Reported by Jules Levin
Presented at the 64th Annual Meeti ng of the American Associati on for the Study of Liver Diseases, November 1-5, 2013, Washington, D.C.
Daniel E Cohen, Wangang Xie, Lois Larsen, Christal Marincic, Mary Knauss-Townsend, Amit Khatri, Thomas Podsadecki, Barry Bernstein
AbbVie Inc., North Chicago, Illinois, United States
|
| |
|
|
|
|
|
